drugset / Trial / NCT00569803
Subcutaneous Pharmacokinetics of Belatacept
RandomizedParallel-groupSingle-blindSupportive care
Summary
Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects
Timeline
- Start
- 2007-12
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Belatacept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Comparator | Belatacept | Protein / enzyme biologic | 100 mg | Subcutaneous |
| Comparator | Belatacept | Protein / enzyme biologic | 125 mg | Subcutaneous |
| Comparator | Belatacept | Protein / enzyme biologic | 150 mg | Subcutaneous |
| Comparator | Belatacept | Protein / enzyme biologic | 200 mg | Subcutaneous |
| Comparator | Belatacept | Protein / enzyme biologic | 250 mg | Subcutaneous |